676479-06-4

676479-06-4 structure

Name: Sembragiline
Chemical Name: Sembragiline
CAS Number: 676479-06-4
Molecular Formula: C₁₉H₁₉FN₂O₃
Molecular Weight: 342.364
Create Date: 2020-01-11 16:59:33
Modify Date: 2025-08-25 23:51:19
Sembragiline (RO4602522, RG1577, EVT 302) is a novel potent, selective, orally available monoamine oxidase B (MAO-B) inhibitor with IC50 of 5.9 nM, >600-fold selectivity over MAO-A; displays no affinity for more than 100 different receptors, enzymes and ion channels; protects against neuronal loss and reduces both ROS formation and reactive astrogliosis in transgenic animal model conditionally overexpressing MAO-B in astroglia, exhibits potential for treatment of Alzheimer's disease (AD) and other neurodegenerative disorders. Alzheimer Disease Phase 2 Clinical

Name	Sembragiline
Synonyms	K3W9672PNJ UNII-K3W9672PNJ Acetamide, N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-3-pyrrolidinyl]- RG1577 Sembragiline N-[(3S)-1-{4-[(3-Fluorobenzyl)oxy]phenyl}-5-oxo-3-pyrrolidinyl]acetamide MFCD28963964

Description	Sembragiline (RO4602522, RG1577, EVT 302) is a novel potent, selective, orally available monoamine oxidase B (MAO-B) inhibitor with IC50 of 5.9 nM, >600-fold selectivity over MAO-A; displays no affinity for more than 100 different receptors, enzymes and ion channels; protects against neuronal loss and reduces both ROS formation and reactive astrogliosis in transgenic animal model conditionally overexpressing MAO-B in astroglia, exhibits potential for treatment of Alzheimer's disease (AD) and other neurodegenerative disorders. Alzheimer Disease Phase 2 Clinical
References	References 1. Borroni E, et al. J Pharmacol Exp Ther. 2017 Sep;362(3):413-423. 2. Nave S, et al. J Alzheimers Dis. 2017;58(4):1217-1228. 3. Yeon SK, et al. Bioorg Med Chem. 2018 Jan 1;26(1):232-244. View Related Products by Target Monoamine Oxidase (MAO) Alzheimer Disease